Free tool
FAERS Monitor: Prometrium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019781 or its brand name (Prometrium, Progesterone). Reports on generic versions are filed under their own applications.
Reports
23,055
Serious
12,952
56% of reports
Hospitalization
3,658
Death reported
504
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache2,101
- fatigue1,832
- off label use1,831
- drug ineffective1,821
- nausea1,506
- pain1,466
- rash976
- dizziness965
- exposure during pregnancy925
- foetal exposure during pregnancy921
- hypersensitivity858
- diarrhoea850
- hyperhidrosis822
- insomnia805
- maternal exposure during pregnancy802
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 227 |
| 2005 | 300 |
| 2006 | 275 |
| 2007 | 243 |
| 2008 | 316 |
| 2009 | 430 |
| 2010 | 532 |
| 2011 | 426 |
| 2012 | 613 |
| 2013 | 507 |
| 2014 | 548 |
| 2015 | 980 |
| 2016 | 1,372 |
| 2017 | 1,087 |
| 2018 | 1,152 |
| 2019 | 1,329 |
| 2020 | 1,386 |
| 2021 | 1,312 |
| 2022 | 1,480 |
| 2023 | 1,687 |
| 2024 | 2,061 |
| 2025 | 2,261 |
| 2026 | 2,531 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| exposure during pregnancySignal | 925 | 13.8 | 12.9 | 10,808 |
| foetal exposure during pregnancySignal | 921 | 10.4 | 9.8 | 7,796 |
| maternal exposure during pregnancySignal | 802 | 8.3 | 7.7 | 5,098 |
| hyperhidrosisSignal | 822 | 5.9 | 5.5 | 3,302 |
| hypersensitivitySignal | 858 | 4.2 | 4.0 | 2,123 |
| headacheSignal | 2,101 | 3.1 | 2.9 | 2,999 |
| insomniaSignal | 805 | 2.8 | 2.6 | 912 |
| painSignal | 1,466 | 2.2 | 2.1 | 961 |
| fatigueSignal | 1,832 | 2.1 | 2.1 | 1,165 |
| rashSignal | 976 | 2.0 | 1.9 | 530 |
| off label use | 1,831 | 1.9 | 1.8 | 825 |
| dizziness | 965 | 1.8 | 1.7 | 327 |
| nausea | 1,506 | 1.7 | 1.7 | 488 |
| drug ineffective | 1,821 | 1.3 | 1.2 | 104 |
| diarrhoea | 850 | 1.2 | 1.1 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.